SENPs | | | | | |
SENP1 | 1) Prostate | Up-regulated | Involve in prostate cancer pathogenesis | Associate with androgen receptor signaling and hypoxia-HIF-1α signaling | Zuo and Cheng (2009) |
2) Colorectal | Up-regulated | Play a role in cell cycle regulation | Up-regulate expression of CDK inhibitors (such as p16, p19, p21, and p27) | Xu et al. (2011) |
3) Pancreatic | Up-regulated | Associate with lymph node metastasis and TNM stage | Associate with MMP-9 which is pivotal for PDAC cell growth and migration | Ma et al. (2014) |
4) Neuroblastoma | Up-regulated | Promote cells migration and invasion | Regulate the expression of CDH1, MMP-9, and MMP-2 | Xiang-Ming et al. (2016) |
5) Multiple myeloma | Up-regulated | Associate with poor prognosis | Associate with NF-кB signaling | Xu et al. (2015) |
SENP2 | 1) Bladder | Down-regulated | Suppress tumor metastasis | Inhibit the expression of MMP-13 | Tan et al. (2013) |
2) Hepatocellular carcinoma | Down-regulated | Play a role in cell growth control | Modulate the stability of β-catenin | Shen et al. (2012) |
SENP3 | 1) Gastric | Up-regulated | Induce specific mesenchymal gene expression in cancer metastasis | Potentiate the transcriptional activity of FOXC2 | Ren et al. (2014) |
2) Oral squamous cell carcinoma | Up-regulated | Correlate with tumor differentiation | Associate with ROS | Sun et al. (2013) |
SENP5 | 1) Breast | Up-regulated | Correlate with poor prognosis | Through SENP5-TGFβ-MMP9 cascade process | Cashman et al. (2014) |
SUMO E1 | | | | | |
SAE1 | 1) Lung adenocarcinoma | Up-regulated | Lower expression in lymph node metastases | — | Inamura et al. (2007) |
SAE2 | 1) Small-cell lung | Up-regulated | Correlate with tumorigenesis in vivo | Decrease chemotherapy sensitivity | Liu et al. (2015) |
2) Breast | Up-regulated | Correlate with survival of the patients. | Associate with oncogenic transcription factor Myc | Kessler et al. (2012) |
SUMO E2 | | | | | |
UBC9 | 1) Liver | Up-regulated | UBC9 directly phosphorylated by cell division cycle 2 | Serine 71 of Ubc9 are required for phosphorylation | Tomasi et al. (2012) |
2) Colon | Up-regulated | Express at high levels in primary cancer | — | Moschos et al. (2010) |
3) Lung | Up-regulated | Express at high levels in primary cancer tissue and metastatic nodules | — | Li et al. (2013) |
4) Breast | Up-regulated | Correlate with poor response to chemotherapy and clinical prognosis | — | Chen et al. (2011) |
5) Melanoma | Up-regulated | Express at high levels in melanoma-positive lymph nodes | — | Moschos et al. (2007) |
6) Glioblastoma | Up-regulated | Promote DNA synthesis and cell growth | Block H2AX phosphorylation which indicates DNA double-strand damage, and G2/M cell cycle arrest | Yang et al. (2013) |
7) Lung adenocarcinoma | Up-regulated | Correlate positively with Dukes’ stage | — | Moschos et al. (2010) |